Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445749 | 1.00 | MEN1 (0.34) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL8678507 | 0.74 | MEN1 (0.39) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL10591170 | 0.68 | CRBN (0.50) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL11911681 | 0.67 | PRKCA (0.33) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL7751354 | 0.67 | ALDH1A1 (0.36) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL28676565 | 0.67 | ALDH1A1 (0.36) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6755435 | 0.66 | KMT2A (0.35) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL19264444 | 0.66 | KMT2A (0.35) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL14895194 | 0.65 | MEN1 (0.32) | MEN1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5868539 | 0.63 | CRBN (0.31) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2022-09-08 | — | — | US | disclosed |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-31 | — | — | US | disclosed |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-17 | — | — | US | disclosed |
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200197466-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP (US) | 2020-06-25 | — | — | US | disclosed |
| US-10639339-B2 | Pharmaceutical composition and method of manufacturing | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10624940-B2 | Pharmaceutical composition and method of manufacturing | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190209633-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2019-07-11 | — | — | US | disclosed |
| US-10238705-B2 | Pharmaceutical composition and method of manufacturing | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190030103-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2019-01-31 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-10639339-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-10238705-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20190030103-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20200197466-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-20190209633-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
| US-10624940-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MEN1 3386/4885ALDH1A1 4647/4885LMNA 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.